Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk

被引:449
作者
Bhattacharyya, Tamali [1 ,2 ]
Nicholls, Stephen J. [1 ,2 ,3 ]
Topol, Eric J. [4 ]
Zhang, Renliang [1 ,2 ]
Yang, Xia [5 ]
Schmitt, David [1 ,2 ]
Fu, Xiaoming [1 ,2 ]
Shao, Mingyuan [3 ]
Brennan, Danielle M. [1 ,3 ]
Ellis, Stephen G. [3 ]
Brennan, Marie-Luise [2 ]
Allayee, Hooman [8 ]
Lusis, Aldons J. [5 ,6 ,7 ]
Hazen, Stanley L. [1 ,2 ,3 ]
机构
[1] Cleveland Clin, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA
[2] Cleveland Clin, Dept Cell Biol, Cleveland, OH 44195 USA
[3] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44195 USA
[4] Scripps Res Inst & Scripps Clin, La Jolla, CA USA
[5] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
[6] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90024 USA
[7] Univ Calif Los Angeles, Dept Immunol, Los Angeles, CA 90024 USA
[8] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2008年 / 299卷 / 11期
关键词
D O I
10.1001/jama.299.11.1265
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Paraoxonase 1 ( PON1) is reported to have antioxidant and cardioprotective properties. The relationship between PON1 genotypes and functional activity with systemic measures of oxidative stress and cardiovascular disease ( CVD) risk in humans has not been systematically investigated. Objective To investigate the relationship of genetic and biochemical determinants of PON1 activity with systemic measures of oxidative stress and CVD risk in humans. Design, Setting, and Participants The association between systemic PON1 activity measures and a functional polymorphism ( Q192R) resulting in high PON1 activity with prevalent CVD and future major adverse cardiac events ( myocardial infarction, stroke, or death) was evaluated in 1399 sequential consenting patients undergoing diagnostic coronary angiography between September 2002 and November 2003 at the Cleveland Clinic. Patients were followed up until December 2006. Systemic levels of multiple structurally defined fatty acid oxidation products were also measured by mass spectrometry in 150 age-, sex-, and race- matched patients and compared with regard to PON1 genotype and activity. Main Outcome Measures Relationship between a functional PON1 polymorphism and PON1 activity with global indices of systemic oxidative stress and risk of CVD. Results The PON1 genotype demonstrated significant dose- dependent associations ( QQ192 > QR192 > RR192) with decreased levels of serum PON1 activity and with increased levels of systemic indices of oxidative stress. Compared with participants with either the PON1 RR192 or QR192 genotype, participants with the QQ192 genotype demonstrated an increased risk of all- cause mortality ( 43/ 681 deaths [ 6.75%] in RR192 and QR192 and 62/ 584 deaths [ 11.1%] in QQ192; adjusted hazard ratio, 2.05; 95% confidence interval [ CI], 1.32- 3.18) and of major adverse cardiac events ( 88/ 681 events [ 13.6%] in RR192 and QR192 and 102/ 584 events [ 18.0%] in QQ192; adjusted hazard ratio, 1.48; 95% CI, 1.09- 2.03; P=. 01). The incidence of major adverse cardiac events was significantly lower in participants in the highest PON1 activity quartile ( 23/ 315 [ 7.3%]) and 235/ 324 [ 7.7%] for paraoxonase and arylesterase, respectively) compared with those in the lowest activity quartile ( 78/ 311 [ 25.1%] and 75/ 319 [ 23.5%]; P <. 001 for paraoxonase and arylesterase, respectively). The adjusted hazard ratios for major adverse cardiac events between the highest and lowest PON1 activity quartiles were, for paraoxonase, 3.4 ( 95% CI, 2.1- 5.5; P <. 001) and for arylesterase, 2.9 ( 95% CI, 1.8- 4.7; P <. 001) and remained independent in multivariate analysis. Conclusion This study provides direct evidence for a mechanistic link between genetic determinants and activity of PON1 with systemic oxidative stress and prospective cardiovascular risk, indicating a potential mechanism for the atheroprotective function of PON1.
引用
收藏
页码:1265 / 1276
页数:12
相关论文
共 31 条
[1]   Polymorphisms in the human paraoxonase (PON1) promoter [J].
Brophy, VH ;
Hastings, MD ;
Clendenning, JB ;
Richter, RJ ;
Jarvik, GP ;
Furlong, CE .
PHARMACOGENETICS, 2001, 11 (01) :77-84
[2]   Paraoxonase and atherosclerosis [J].
Durrington, PN ;
Mackness, B ;
Mackness, MI .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (04) :473-480
[3]  
ECKERSON HW, 1983, AM J HUM GENET, V35, P1126
[4]   The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux [J].
Gaidukov, Leonid ;
Rosenblat, Mira ;
Aviram, Michael ;
Tawfik, Dan S. .
JOURNAL OF LIPID RESEARCH, 2006, 47 (11) :2492-2502
[5]   EVALUATING THE YIELD OF MEDICAL TESTS [J].
HARRELL, FE ;
CALIFF, RM ;
PRYOR, DB ;
LEE, KL ;
ROSATI, RA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1982, 247 (18) :2543-2546
[6]   Paraoxonase genes and disease [J].
Hegele, RA .
ANNALS OF MEDICINE, 1999, 31 (03) :217-224
[7]   Validating a prognostic model [J].
Kattan, Michael W. .
CANCER, 2006, 107 (11) :2523-2524
[8]   Evaluating a new marker's predictive contribution [J].
Kattan, MW .
CLINICAL CANCER RESEARCH, 2004, 10 (03) :822-824
[9]   The association of the PONI Q192R polymorphism with coronary heart disease:: findings from the British Women's Heart and Health cohort study and a meta-analysis -: art. no. 17 [J].
Lawlor, DA ;
Day, INM ;
Gaunt, TR ;
Hinks, LJ ;
Briggs, PJ ;
Kiessling, M ;
Timpson, N ;
Smith, GD ;
Ebrahim, S .
BMC GENETICS, 2004, 5 (1)
[10]   Paraoxonase gene polymorphisms, oxidative stress, and diseases [J].
Li, HL ;
Liu, DP ;
Liang, CC .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2003, 81 (12) :766-779